The United States of America, As Represented by the Secretary, Department of Health and Human Services

The University of North Carolina at Chapel Hill

University of Kansas

Amy Elizabeth Moritz

Noel Terrence Southall

Xin Hu

Kevin Frankowski

Marc Ferrer

Warren S Weiner

David Robert Sibley

Joseph Perry Steiner

Jeffrey Aubé

R Benjamin Free

Jeffrey AubÉ

The disclosure of a compound of Formula I or a pharmaceutically acceptable salt thereof

Selective D3 dopamine receptor agonists and methods of their use

The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R, R, R, and Rare defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.

Selective Ddopamine receptor agonists and methods of their use

Growing community of inventors

Bethesda, MD, United States of America

Amy Elizabeth Moritz